PRODUCT INFORMATION

Crizotinib-d_5

Item No. 26762

CAS Registry No.:	1395950-84-1
Formal Name:	3-[(1R)-1-(2,6-dichloro-3-fluorophenyl) ethoxy]-5-[1-(4-piperidinyl-3,3,4,5,5-d_5)-1H-pyrazol-4-yl]-2-pyridinamine
MF:	$C_{21}H_{17}Cl_2D_5FN_5O$
FW:	455.4
Chemical Purity:	≥98% (Crizotinib)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_5); ≤1% d_0
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Crizotinib-d_5 is intended for use as an internal standard for the quantification of crizotinib (Item No. 12087) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Crizotinib-d_5 is supplied as a solid. A stock solution may be made by dissolving the crizotinib-d_5 in the solvent of choice. Crizotinib-d_5 is soluble in the organic solvent chloroform, which should be purged with an inert gas.

Description

Crizotinib is a derivative of aminopyridine that acts as a potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC_{50} = 8 nM) and ALK (IC_{50} = 20 nM) receptor tyrosine kinases.[1] Crizotinib shows antitumor efficacy, including cytoreductive antitumor activity, in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC_{50}s = 5-20 nM).[1,2]

References

1. Cui, J.J., Tran-Dubé, M., Shen, H., *et al.* Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). *J. Med. Chem.* **54(18)**, 6342-6363 (2011).
2. Tanizaki, J., Okamoto, I., Okamoto, K., *et al.* MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. *J. Thorac. Oncol.* **6(10)**, 1624-1631 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM